Cancer-related cognitive impairment in non-CNS cancer patients: Targeted review and future action plans in Europe
Charlotte Sleurs(Catholic University of America), Joy Perrier(Inserm), Cecilie R. Buskbjerg(Aarhus University), Ali Amidi(Aarhus University), Mylène Duivon(Inserm), Djihane Ahmed-Lecheheb(Inserm), Philipp Zimmer(TU Dortmund University), Bénédicte Giffard(Inserm), David Kiesl(Kepler Universitätsklinikum), Anne Rogiers(Centre Hospitalier Universitaire Brugmann), Marie Lange(Inserm), Florence Joly(Centre François Baclesse), Sanne B. Schagen(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Sabine Deprez(VIB-KU Leuven Center for Brain & Disease Research), Mélanie Dos Santos(Inserm), Hélène Castel(Inserm), Cindy Borghgraef(Université Libre de Bruxelles), Lisa M. Wu(Northwestern University), Michiel de Ruiter(The Netherlands Cancer Institute), Giulia Binarelli(University Hospital of Lausanne)
Cited by 29
Related Papers
Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy
|JNCI Journal of the National Cancer Institute|1998|768
BRAF Inhibition in <i>BRAF</i> <sup>V600</sup> -Mutant Gliomas: Results From the VE-BASKET Study
|Journal of Clinical Oncology|2018|330
Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial
|Journal of Clinical Oncology|2010|261
Late effects of adjuvant chemotherapy on cognitive function:a follow-up study in breast cancer patients
|Annals of Oncology|2002|260
An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32)
|European Journal of Cancer|2005|241